NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
Biotechnology company BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT) is working to develop a novel, personalized immunotherapy treatment for patients with advanced breast cancer. A recent article further discussing BriaCell reads, “Improving the efficacy, safety and cost of care for those who are annually diagnosed with breast cancer continues to be at the forefront of medical research. An estimated 266,120 new cases of breast cancer are projected to be diagnosed in U.S. women during 2018, according to the National Cancer Institute (NCI) (http://nnw.fm/5WWsU). Female breast cancer represents 15.3 percent of all new cancer cases in the U.S., with nearly 41,000 women expected to die of the disease in 2018, according to the NCI. Breast cancer is identified as the most commonly occurring cancer in women around the globe and the second most common cancer overall, according to the World Cancer Research Fund International (http://nnw.fm/7yLRz). ”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer